Targeted Oncology Staff

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed elements to diagnosing myelofibrosis and how to approach risk stratification before treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed trials of immune checkpoint inhibition and when to discontinue treatment in patients with endometrial cancer. This is the second of 2 articles based on this event.

In the second article of a 2-part series, Rana McKay, MD, discussed follow-up analyses of the phase 3 CheckMate 9ER trial that showed the benefit of nivolumab plus cabozantinib vs sunitinib for patients with advanced renal cell carcinoma.

In a live, virtual event, Chakra Chaulagain, MD, discussed the results of the GRIFFIN trial in patients with newly diagnosed multiple myeloma when adding daratumumab to their traditional triplet therapy.

In separate live virtual events, Pashna N. Munshi, MD; Navneet Majhail, MD, MS; and participants at the respective discussions considered treatment options for a patient with chronic graft-vs-host disease (GVHD) after multiple previous treatment attempts.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with other oncologists concerning the practical considerations for outpatient use of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasm.

During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, and participants discussed the role of JAK inhibitors in managing myelofibrosis particularly in younger patients who may receive allogeneic stem cell transplant. This is the first of 2 articles based on this event.

In the first article of a 2-part series, Ajay Nooka, MD, MPH, discussed both the initial and follow-up results of the MajesTEC-1 trial that showed the potency of teclistamab in patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.

During a Targeted Oncology™ Case-Based Roundtable™ event, David Zhen, MD, explored treatment options for patients with advanced HER2-negative upper gastrointestinal cancers.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, and participants discussed second-line therapy options for a patient with high-risk relapsed multiple myeloma after frontline lenalidomide, bortezomib, and dexamethasone followed by autologous stem cell transplant.

During a Targeted Oncology™ Case-Based Roundtable™ event, Gabriela S. Hobbs, MD, reviewed the data for frontline use of JAK inhibitors to treat patients with primary myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Aditya Bardia, MD, MPH, discussed treatment approaches for a patient with hormone receptor–positive, HER2- negative metastatic breast cancer?

In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed biopsy and treatment approaches for a patient diagnosed with T2aN2M0, stage IIIA adenocarcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, PhD, discussed the phase 2 data for osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer and what they suggest for the upcoming phase 3 FLAURA2 trial results.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the frontline tyrosine kinase inhibitor/immune checkpoint inhibitor regimens and how to manage toxicities related to these regimens.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer.

At a live virtual event, Rahul Aggarwal, MD, discussed the addition of olaparib to the treatment of patients with metastatic castration-resistant prostate cancer harboring certain gene mutations.

During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, discussed treatment approaches for a 78-year-old patient with metastatic melanoma discovered 12 years after surgical resection.

In the first article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on considerations for the treatment of patients with relapsed/refractory renal cell carcinoma in the third-line setting.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carrie L. Kitko, MD, discussed whether to biopsy a patient with chronic GVHD and what treatment to use following steroids.

In the first article of a 2-part series, Mehmet A. Blien, MD, discusses where cabazitaxel fits into the treatment paradigm for patients with metastatic castration resistant prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed the treatment options for a patient with endometrial cancer who relapsed following resection and again following a complete response to chemotherapy. This is the first of 2 articles based on this event.

In the first article of a 2-part series, Rana McKay, MD, goes through the updated data from the CheckMate 9ER trial that supports the continued use of the combination of nivolumab and cabozantinib for patients with metastatic clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the role of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.

In this first part of a 2-article series, Joyce O’Shaughnessy, MD, recent updates to treatment and testing guidelines for patients with advanced breast cancer whose disease harbors an ESR1 mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.